Here’s a roundup of the latest coronavirus-related news from this week.
Infectious Diseases & Conditions
Gilead has now asked the FDA to rescind its orphan drug status for the potential COVID-19 therapy.
Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.
CVS Caremark’s new quantity limits will not affect members who are already receiving these medications for their approved uses.
Convalescent plasma, hydroxychloroquine, and remdesivir among the potential COVID-19 treatment pathways being pursued.
A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.
The announcement follows their previous commitment to offering COVID-19 testing at local hospitals.
Pediatricians stress the importance of understanding the effects of COVID-19 on children.
Due to the increased need for albuterol inhalers in hospitals for COVID-19, shortages have been occurring in some areas of the country and will likely continue to affect supplies.
Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.